TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor July 8, 2024 • 6:30 AM EDT
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones July 1, 2024 • 8:35 AM EDT
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) June 3, 2024 • 8:35 AM EDT
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results May 14, 2024 • 4:45 PM EDT
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement April 3, 2024 • 7:00 AM EDT
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab March 27, 2024 • 9:00 AM EDT
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update February 14, 2024 • 4:07 PM EST
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer February 12, 2024 • 9:00 AM EST
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement December 5, 2023 • 9:00 AM EST